

**Table 9.6a**  
**Immunosuppression Use for Induction, 1999 to 2008**  
**Recipients with Liver Transplants**

	Year of Transplant									
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008
<b>Transplants</b>	4,751	4,997	5,196	5,332	5,673	6,171	6,444	6,651	6,494	6,318
<b>With Immunosuppression Info</b>	4,442	4,846	5,034	5,198	5,520	5,974	6,164	6,407	6,276	6,125
<b>Induction Drugs</b>										
ALG	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	0.7%	0.7%	0.4%	0.5%	0.5%	0.4%	0.2%	0.3%	1.2%	1.1%
OKT3	1.4%	0.8%	0.7%	0.3%	0.3%	0.2%	0.8%	2.7%	2.9%	2.5%
Thymoglobulin	0.5%	1.2%	2.4%	4.2%	6.5%	7.4%	7.3%	8.9%	9.5%	10.3%
Zenapax	6.6%	6.6%	5.8%	4.6%	5.6%	4.7%	4.0%	5.8%	8.1%	7.9%
Simulect	4.4%	6.6%	6.2%	7.8%	7.2%	6.4%	7.1%	6.5%	5.6%	6.7%
Campath	0.0%	0.0%	0.0%	0.0%	0.7%	1.6%	1.6%	1.4%	1.4%	1.0%
<b>No Induction Drugs Recorded</b>	86.7%	84.5%	84.6%	82.7%	79.5%	79.5%	79.9%	77.2%	74.4%	73.4%

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.